Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us.

Nature communications - 25 May 2026

Salvatore Maxwell, Zhang Bingyu, Tang Huilin, Lu Yiwen, Zhang Dazheng, Zhou Ting, Lu Yuan, Amaro Anastassia, D Ritchie Marylyn, Chen Yong

Abstract excerpt

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes (T2D) and weight management, yet their real-world health impacts remain understudied. Using a retrospective cohort design with electronic health record data from 17,267 adults with type 2 diabetes in the All of Us Research Program, we conduct propensity score-matched phenome-wide association studies comparing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Diabetes Mellitus, Type 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Electronic Health Records

Share to Hypoglycemic Agents

Share to Phenomics

Share to Phenotype

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 42185271
DOI: 10.1038/s41467-026-72947-y
PMCID: PMC13388941

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us.PMID 42185271Read ↗

GLP Medications and Severe Post-COVID-19 Outcomes Among Individuals with Type 2 Diabetes MellitusSemantic proximity Read ↗

Oral Health Outcomes with GLP1 Receptor Agonists Compared with Other Metabolic InterventionsSemantic proximity Read ↗

GLP1R gene expression is associated with metabolic and mental health effects in a phenome-wide drug repurposing and safety analysisSemantic proximity Read ↗

Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM StudySemantic proximity Read ↗

Neurosensory Risk After Semaglutide or Tirzepatide Is Lower Than Matched Antidiabetic and Bariatric Surgery Cohorts and Tracks Glycemic BurdenSemantic proximity Read ↗

Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes: An Umbrella ReviewSemantic proximity Read ↗

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A 2x2 Factorial Mendelian Randomization StudySemantic proximity Read ↗

Distinct glycaemic safety reporting patterns for alpelisib and capivasertib: a disproportionality analysis of the FAERS databaseSemantic proximity Read ↗

Cardiorenal outcomes of tirzepatide versus semaglutide in adults with type 2 diabetes and chronic kidney disease: a target trial emulation in the TriNetX Global Collaborative NetworkSemantic proximity Read ↗

Identification and genetic validation of drug-comorbidity interactions in type 2 diabetes using data-driven disease trajectory analysisSemantic proximity Read ↗

Heterogeneity of Treatment Effects of Glucose-lowering Drug Classes for Type 2 Diabetes: LEGEND-T2DM Network Real-World EvidenceSemantic proximity Read ↗

Pharmacogenomics of GLP-1 Receptor Agonists: Precision Medicine in the Age of Ozempic and MounjaroSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.